Scancell progresses its new anti-glycan monoclonal antibody (mAb) platform GlyMab™
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “We believe our proprietary GlyMab™ platform provides a powerful and versatile approach to generating novel antibody drug candidates that bind to sugar motifs, rather than peptide epitopes, found on the surface of glycosylated proteins and lipids that are implicated as drug targets in particular cancers and potentially other diseases. As such, this new platform expands on Scancell’s unique approach to developing innovative therapies for cancer and infectious disease. The Board believes that there are multiple ways to maximise the value of these innovative and proprietary assets, either developing them internally to further value inflection points, develop alongside strategic partners or through earlier stage commercial licences. The fourth research agreement on the Glymab™ platform provides further validation of the commercial potential of this platform.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data